Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Neurovalens

Neurovalens
2013 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Early Stage VC LATEST DEAL TYPE
$6.22M LATEST DEAL AMOUNT
7 INVESTORS
Description

Developer of wearable neurostimulation devices designed to control appetite and cravings. The company's devices non-invasively stimulates the area of the brain to induce a metabolic shift within the body and restrict the diet consumption by making the person feel full quickly, enabling people to lose weight in a simple and hassle-free manner.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • 4th Floor
  • 7 James Street South
  • Belfast BT2 8DN
  • Northern Ireland, United Kingdom
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Neurovalens’s full profile, request a free trial.

Neurovalens Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 15-Mar-2019 $6.22M 00.000 000.00 Completed Generating Revenue
4. Product Crowdfunding 07-Oct-2017 00.00 00.00 Completed Generating Revenue
3. Seed Round 19-Jul-2017 00.000 00.00 00.000 Completed Generating Revenue
2. Seed Round 01-Dec-2016 $355K $386K Completed Startup
1. Accelerator/Incubator 27-Oct-2015 $30.7K $30.7K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Neurovalens Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
A Preferred 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Preferred Ordinary 000,000 00.000000 00.0 00.0 00 00.0 0.000
Preferred Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Preferred Ordinary 480,236 $0.000001 $1.44 $1.44 1x $1.44 4.91%
Ordinary 194,598 $0.000001 $1.44 $1.44 1x $1.44 1.99%
To view this company’s complete Cap Table, request access »

Neurovalens Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Clarendon Fund Managers Venture Capital Minority 000 0000 000000 0
IQ Capital Partners Venture Capital Minority 000 0000 000000 0
Wharton Asset Management Family Office Minority 000 0000 000000 0
Angel CoFund Angel Group Minority 000 0000 000000 0
Beltrae Partners PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Neurovalens Executive Team (3)

Name Title Board
Seat
Contact
Info
Jason McKeown Co-Founder, Board Member & Chief Executive Officer
Niall Quinn Board Member & Chief Financial Officer
Paul Mcgeoch Advisor & Co-Founder

Neurovalens Board Members (8)

Name Representing Role Since Contact
Info
Gaby Salem Wharton Asset Management Board Member 000 0000
Ian Kerr Ph.D Beltrae Partners Chairman 000 0000
Imran Liaquat Neurovalens Board Member 000 0000
James Andrews Techstart Ventures Board Member 000 0000
Jason McKeown Neurovalens Co-Founder, Board Member & Chief Executive Officer 000 0000
You’re viewing 5 of 8 board members. Get the full list »